Combidex NDA accepted for FDA review

被引：0

|

作者：

不详

机构：

来源：

DRUG NEWS & PERSPECTIVES | 2000年 / 13卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

下载

收藏

页码：64 / 64

页数：1

相关论文

共 50 条

[1] Lidakol NDA accepted for review
不详
DRUG NEWS & PERSPECTIVES, 1998, 11 (02) : 126 - 126
[2] Cellegesic NDA accepted for review
不详
DRUG NEWS & PERSPECTIVES, 2004, 17 (07) : 438 - 438
[3] FDA to continue review of Relenza NDA
不详
DRUG NEWS & PERSPECTIVES, 1999, 12 (03) : 182 - 182
[4] GelTex NDA for RenaGel non-absorbed phosphate binder accepted as filable by FDA
不详
DIALYSIS & TRANSPLANTATION, 1998, 27 (03) : 130 - +
[5] Belotero® Balance PMA Filing Accepted for Review by FDA
不详
JOURNAL OF DRUGS IN DERMATOLOGY, 2009, 8 (11) : 1051 - 1051
[6] FDA Announces Priority Review of 18F-DCFPyL NDA
不详
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (02) : 21N - 21N
[7] FDA BACKS PAPER NDA POLICY
不详
AMERICAN PHARMACY, 1981, 21 (02): : 7 - 8
[8] NDA application for Temodal submitted to FDA
不详
DRUG NEWS & PERSPECTIVES, 1998, 11 (06) : 379 - 379
[9] Anesta submits NDA for Actiq to US FDA
不详
DRUG NEWS & PERSPECTIVES, 1996, 9 (10) : 621 - 621
[10] Best practices for communication between FDA and applicants during the NDA review cycle: A PhRMA white paper
Cocchetto, David M.
Stotka, Jennifer L.
Zezza, Diane
Hassall, Thomas H.
Brophy, Gregory
Peterson, Donna
DRUG INFORMATION JOURNAL, 2008, 42 (01): : 3 - 8

← 1 2 3 4 5 →